Reimbursed Care Access in Northern Mariana Islands

Currently classified as a strictly controlled substance under U.S. federal scheduling (Schedule I) with no authorized medical use in routine clinical practice — access in the CNMI is limited to FDA‑regulated clinical research or special approvals. Federal scheduling and DEA/CFR listings apply to the Northern Mariana Islands because it is a U.S. territory; therefore psilocybin is not available as a reimbursed therapy outside of approved trials. #

Currently classified as a strictly controlled substance under national (U.S. federal) drug scheduling laws (Schedule I), with authorized use limited to approved clinical research programs; no routine medical reimbursement or outpatient medical access in the CNMI outside of these trials. Ongoing US‑based investigator‑initiated and company‑sponsored trials (e.g., for PTSD) follow federal DEA/IRB/independent review processes; any participation by CNMI residents would require investigators to hold appropriate DEA registrations and local facility approvals. #

Esketamine (Spravato) is FDA‑approved for specific depressive indications and is distributed only through a REMS program that requires certified healthcare settings and provider monitoring; these federal requirements apply in U.S. territories including the Northern Mariana Islands. The product’s REMS restricts administration to certified sites and requires post‑dose monitoring (at least two hours), and it cannot be dispensed for unsupervised home use. # #.

Regulatory and reimbursement nuance in CNMI: because CNMI is a U.S. territory, FDA approval and REMS requirements are applicable; however practical access and reimbursement depend on (1) whether a certified REMS site exists locally (hospital/clinic certified by Janssen/REMS), (2) the territory’s payer mix (private commercial plans, local Medicaid/CHC arrangements), and (3) manufacturer/distributor supply and contractual arrangements. Territories were incorporated into some federal drug rebate and program definitions beginning in regulatory changes effective January 1, 2023, but participation and operational details differ by territory and payer — meaning coverage by territorial Medicaid or local public plans may vary and often lags availability in the 50 states. # #.

Practical reimbursement considerations: commercially insured patients in CNMI may obtain coverage consistent with plan terms if the plan recognizes Spravato and authorizes REMS‑site administration (many commercial plans in U.S. jurisdictions cover Spravato with prior authorization). Medicare (and Medicare Advantage) have established billing pathways for esketamine administered in clinical settings in the U.S.; Medicare/Medicaid coverage in CNMI follows U.S. statutory/regulatory frameworks but local implementation and provider enrollment determine whether a local beneficiary can be billed/covered in practice. Patients should confirm local REMS site availability and payer prior‑authorization policies before assuming coverage. # #

Ketamine (racemic ketamine; Schedule III at the federal level) is an FDA‑approved anesthetic that is widely used off‑label in many jurisdictions for depression, PTSD, and pain syndromes via IV/IM infusions in private clinics; these off‑label infusion services operate outside FDA indications and reimbursement is inconsistent. As a U.S. territory, CNMI follows the same federal scheduling (ketamine is Schedule III) and clinicians may legally prescribe ketamine off‑label, but the usual commercial and public payers in U.S. jurisdictions generally do not reimburse IV ketamine for psychiatric indications because it is considered investigational/off‑label; esketamine (Spravato) is the only ketamine‑derived antidepressant with an established FDA‑approved and REMS‑governed reimbursement pathway. # #.

Local CNMI implications: private ketamine infusion clinics (if present or via referral to nearby U.S. clinics) will typically require self‑pay or private insurer pre‑approval; Medicare/Medicaid reimbursement for off‑label ketamine infusions is uncommon and will depend on specific local carrier policies and documented medical necessity. Providers and patients in CNMI should verify local facility licensing, DEA registration for controlled substance handling, and payer prior‑authorization policies before care. #

Currently classified as a Schedule I substance under U.S. federal law (no accepted medical use for routine care), with access limited to authorized clinical research; any research or medical program in CNMI would require DEA registration, FDA/IRB approvals, and local facility authorization. #

Currently classified among tryptamine psychedelics controlled under federal law (practical access limited to approved research); no routine medical or reimbursed pathway exists in the CNMI. Participation in trials would require federal and local approvals. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Federal scheduling and the lack of approved indications mean no routine medical access or reimbursement exists in the CNMI. #

Because ayahuasca preparations contain DMT (a Schedule I substance in the United States), ayahuasca is controlled under federal law and is not an authorized reimbursed medical therapy; access is limited to approved clinical research or narrow, specific religious exemptions recognized under U.S. federal law for certain bona fide Native American or religious organizations (which remain exceptional and fact‑specific). Routine medical reimbursement is not available in the CNMI. # #

Mescaline is federally controlled (Schedule I) in the United States; its sanctioned non‑criminal use is effectively limited to narrow religious exemptions (e.g., bona fide Native American Church practices) and to regulated scientific research. There is no routine medical reimbursement pathway for mescaline in the CNMI. #

Currently classified as a strictly controlled set of phenethylamine/entactogen substances under U.S. federal law (substances of the 2C family are treated as controlled/illegal where applied), with no authorized medical use outside approved research; no reimbursed medical access exists in the CNMI. #